enGene Therapeutics Inc. (ENGN)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Ronald H. W. Cooper
|
President, CEO & Director | 1.21M | -- | 1963 |
|
Dr. William J. Grossman M.D., Ph.D.
|
Interim Chief Medical Officer & Director | 15.99k | -- | 1970 |
|
Ms. Kathleen Richton
|
Senior VP of Finance, Principal Accounting & Financial Officer and Controller | -- | -- | 1978 |
|
Ms. Joan Connolly
|
Chief Technology Officer | -- | -- | 1970 |
|
Ms. Tara Place M.B.A.
|
Senior VP of Human Resources | -- | -- | -- |
|
Dr. Anthony T. Cheung Ph.D.
|
Consultant | 341.75k | -- | 1972 |
|
Mr. Matthew Boyd
|
Chief Regulatory Officer | -- | -- | 1974 |
|
Ms. Jill Buck
|
Chief Development Officer | -- | -- | 1974 |
|
Ms. Amy Pott
|
Chief Global Commercialization Officer | -- | -- | 1976 |
enGene Therapeutics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 81
Description
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Corporate Governance
Upcoming Events
December 22, 2026 at 1:30 PM UTC
enGene Therapeutics Inc. Earnings Date
